Phreesia (PHR) Projected to Post Quarterly Earnings on Wednesday

Phreesia (NYSE:PHR) is expected to release its Q4 2026 results before the market opens on Wednesday, March 11th. Analysts expect Phreesia to post earnings of $0.10 per share for the quarter. Investors can check the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Monday, March 30, 2026 at 5:00 PM ET.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. The business had revenue of $120.33 million for the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The business’s revenue for the quarter was up 12.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.25) EPS. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Stock Performance

NYSE:PHR opened at $12.06 on Monday. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $727.10 million, a price-to-earnings ratio of -120.59 and a beta of 0.67. The firm’s fifty day simple moving average is $14.24 and its 200 day simple moving average is $19.73. Phreesia has a twelve month low of $11.31 and a twelve month high of $32.76.

Analyst Ratings Changes

Several research firms have commented on PHR. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price objective on shares of Phreesia in a research report on Monday, December 8th. DA Davidson decreased their target price on Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Truist Financial set a $24.00 target price on Phreesia in a research note on Thursday, January 8th. Mizuho set a $22.00 target price on Phreesia in a report on Wednesday, February 4th. Finally, Robert W. Baird reduced their price target on Phreesia from $31.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 10th. Seventeen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Phreesia presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.12.

Insider Buying and Selling

In other news, General Counsel Allison C. Hoffman sold 6,585 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $112,010.85. Following the completion of the sale, the general counsel directly owned 174,762 shares in the company, valued at $2,972,701.62. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Amy Beth Vanduyn sold 2,602 shares of Phreesia stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $44,260.02. Following the sale, the senior vice president directly owned 160,238 shares in the company, valued at approximately $2,725,648.38. The trade was a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 60,766 shares of company stock worth $1,013,817 over the last quarter. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Campbell & CO Investment Adviser LLC purchased a new position in shares of Phreesia during the 4th quarter valued at approximately $433,000. Vinva Investment Management Ltd increased its stake in shares of Phreesia by 31.0% in the fourth quarter. Vinva Investment Management Ltd now owns 23,846 shares of the company’s stock worth $403,000 after buying an additional 5,643 shares during the last quarter. Raymond James Financial Inc. increased its stake in shares of Phreesia by 2.7% in the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock worth $400,000 after buying an additional 375 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Phreesia by 128.2% in the second quarter. BNP Paribas Financial Markets now owns 12,284 shares of the company’s stock valued at $350,000 after acquiring an additional 6,902 shares in the last quarter. Finally, PharVision Advisers LLC acquired a new stake in Phreesia in the third quarter valued at $345,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.